Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $56.35.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, October 8th.

Institutional Trading of Zai Lab

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in Zai Lab in the third quarter valued at approximately $331,000. Acadian Asset Management LLC acquired a new position in shares of Zai Lab in the 1st quarter valued at $1,073,000. MPM Bioimpact LLC increased its position in shares of Zai Lab by 4.2% in the 1st quarter. MPM Bioimpact LLC now owns 833,659 shares of the company’s stock valued at $30,128,000 after buying an additional 33,659 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Zai Lab during the 1st quarter worth $12,649,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in Zai Lab by 29.0% during the first quarter. Cubist Systematic Strategies LLC now owns 93,645 shares of the company’s stock worth $3,384,000 after acquiring an additional 21,026 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB opened at $18.33 on Monday. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -9.40 and a beta of 0.87. The company has a 50 day moving average of $21.43 and a 200-day moving average of $30.03. Zai Lab has a one year low of $16.82 and a one year high of $44.34.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Zai Lab had a negative net margin of 46.83% and a negative return on equity of 25.83%. The business had revenue of $116.10 million during the quarter, compared to the consensus estimate of $150.24 million. Equities research analysts anticipate that Zai Lab will post -2.58 earnings per share for the current year.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.